Brazil
Egypt
Europe
Hong Kong
Malaysia
Mexico
Morocco
Philippines
Saudi Arabia
South Africa
Taiwan
Thailand
Tunisia
Turkey
UAE
USA
Vietnam
Global HQ
Biocon’s Insulin Manufacturing Facility in Malaysia Receives EIR from U.S. FDA with Voluntary Action Indicated (VAI) Classification, Inspection Stands Closed
-
Wed, 01-Apr-2020
- Posted by: Biocon Biologics
No Comments
Biocon & Biocon Biologics Ensuring Manufacturing of Life-Saving Medicines for Patients, Partners and Customers
-
Fri, 27-Mar-2020
- Posted by: Biocon Biologics
Biocon & Mylan Win Patent Litigation Asserted by Sanofi for Insulin Glargine Device Patent in U.S.
-
Wed, 11-Mar-2020
- Posted by: Biocon Biologics
U.S. FDA Accepts Biologics License Application (BLA) for Mylan and Biocon’s Proposed Biosimilar Bevacizumab for Review
-
Mon, 09-Mar-2020
- Posted by: Biocon Biologics
Biocon’s Insulin Manufacturing Facility in Malaysia Completes U.S. FDA (PAI) Inspection
-
Sat, 22-Feb-2020
- Posted by: Biocon Biologics
Kiran Mazumdar-Shaw Named EY Entrepreneur of the Year India 2019
-
Thu, 20-Feb-2020
- Posted by: Biocon Biologics
Biocon Q3FY20 Earnings Revenue at Rs 1,784 Cr, Up 14%; EBITDA at Rs 480 Cr, Up 18%; Net Profit (before exceptional item) at Rs 225 Cr, Up 6%
-
Thu, 23-Jan-2020
- Posted by: Biocon Biologics
Kiran Mazumdar-Shaw Honoured with Order of Australia, Australia’s Highest Civilian Honour
-
Sat, 18-Jan-2020
- Posted by: Biocon Biologics
True North to Invest Rs 536.25 Crore in Biocon Biologics for 2.44% Stake
-
Mon, 06-Jan-2020
- Posted by: Biocon Biologics
Biocon Biologics Appoints M.B. Chinappa as Chief Financial Officer
-
Mon, 06-Jan-2020
- Posted by: Biocon Biologics
